 Katy Trinkley
Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Decision Support Systems, Clinical | 10 | 2025 | 205 | 4.820 |
Why?
| | Long QT Syndrome | 6 | 2025 | 67 | 3.120 |
Why?
| | Pharmacists | 7 | 2019 | 247 | 2.760 |
Why?
| | Primary Health Care | 9 | 2020 | 1680 | 1.910 |
Why?
| | Electronic Health Records | 11 | 2025 | 975 | 1.590 |
Why?
| | Medical Order Entry Systems | 2 | 2021 | 43 | 1.310 |
Why?
| | Pharmacy Service, Hospital | 3 | 2019 | 90 | 1.300 |
Why?
| | Irritable Bowel Syndrome | 3 | 2015 | 28 | 1.270 |
Why?
| | Lisinopril | 2 | 2020 | 14 | 1.260 |
Why?
| | Heart Failure | 6 | 2023 | 2150 | 1.210 |
Why?
| | Practice Patterns, Physicians' | 5 | 2020 | 1266 | 1.150 |
Why?
| | Physicians | 3 | 2023 | 865 | 1.000 |
Why?
| | Hypertension | 4 | 2020 | 1242 | 1.000 |
Why?
| | Artificial Intelligence | 2 | 2024 | 246 | 0.870 |
Why?
| | Constipation | 3 | 2015 | 88 | 0.850 |
Why?
| | Professional Role | 3 | 2019 | 158 | 0.770 |
Why?
| | Interprofessional Relations | 2 | 2015 | 277 | 0.760 |
Why?
| | Electrocardiography | 4 | 2024 | 608 | 0.730 |
Why?
| | Losartan | 1 | 2020 | 14 | 0.710 |
Why?
| | Angioedema | 1 | 2020 | 16 | 0.700 |
Why?
| | Pharmaceutical Services | 2 | 2019 | 81 | 0.680 |
Why?
| | Medication Adherence | 2 | 2025 | 558 | 0.650 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 201 | 0.640 |
Why?
| | Antihypertensive Agents | 2 | 2020 | 485 | 0.640 |
Why?
| | Antipsychotic Agents | 2 | 2018 | 195 | 0.630 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 171 | 0.620 |
Why?
| | Humans | 47 | 2025 | 129650 | 0.610 |
Why?
| | Dementia | 2 | 2018 | 227 | 0.570 |
Why?
| | Pharmacies | 2 | 2019 | 36 | 0.550 |
Why?
| | Community Pharmacy Services | 1 | 2017 | 43 | 0.550 |
Why?
| | Health Personnel | 2 | 2020 | 652 | 0.540 |
Why?
| | Chronic Pain | 2 | 2019 | 254 | 0.530 |
Why?
| | Depression | 4 | 2019 | 1307 | 0.520 |
Why?
| | Analgesics, Opioid | 3 | 2024 | 913 | 0.510 |
Why?
| | Referral and Consultation | 2 | 2019 | 732 | 0.510 |
Why?
| | Program Development | 1 | 2018 | 357 | 0.510 |
Why?
| | Nursing Informatics | 1 | 2016 | 27 | 0.500 |
Why?
| | Benzodiazepines | 1 | 2016 | 136 | 0.490 |
Why?
| | Torsades de Pointes | 2 | 2024 | 22 | 0.480 |
Why?
| | Patient Transfer | 1 | 2017 | 162 | 0.480 |
Why?
| | Students, Pharmacy | 1 | 2016 | 96 | 0.470 |
Why?
| | Cyclohexanols | 1 | 2014 | 12 | 0.470 |
Why?
| | Aged | 15 | 2025 | 22103 | 0.460 |
Why?
| | Education, Pharmacy | 1 | 2016 | 119 | 0.460 |
Why?
| | Pain Management | 1 | 2017 | 327 | 0.450 |
Why?
| | Patient Care Team | 2 | 2016 | 605 | 0.450 |
Why?
| | Stroke Volume | 3 | 2023 | 592 | 0.440 |
Why?
| | Fibromyalgia | 1 | 2014 | 56 | 0.440 |
Why?
| | Retrospective Studies | 11 | 2023 | 14518 | 0.440 |
Why?
| | Blood Pressure | 2 | 2020 | 1736 | 0.440 |
Why?
| | Registries | 2 | 2020 | 1896 | 0.440 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 253 | 0.430 |
Why?
| | Nurse Practitioners | 1 | 2016 | 132 | 0.430 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 60 | 0.420 |
Why?
| | Phentermine | 1 | 2013 | 9 | 0.420 |
Why?
| | Middle Aged | 16 | 2025 | 31154 | 0.410 |
Why?
| | Sleep Wake Disorders | 1 | 2016 | 252 | 0.410 |
Why?
| | Patient Safety | 1 | 2016 | 287 | 0.410 |
Why?
| | Medical Informatics | 1 | 2014 | 99 | 0.400 |
Why?
| | Telemedicine | 3 | 2020 | 788 | 0.400 |
Why?
| | Fructose | 1 | 2013 | 106 | 0.400 |
Why?
| | Anti-Obesity Agents | 1 | 2013 | 53 | 0.400 |
Why?
| | Cooperative Behavior | 1 | 2015 | 433 | 0.390 |
Why?
| | User-Computer Interface | 1 | 2013 | 149 | 0.380 |
Why?
| | Metformin | 1 | 2015 | 315 | 0.380 |
Why?
| | Patient Discharge | 1 | 2017 | 857 | 0.360 |
Why?
| | Pharmacogenetics | 2 | 2024 | 175 | 0.350 |
Why?
| | Ambulatory Care | 3 | 2023 | 504 | 0.320 |
Why?
| | Internet | 1 | 2014 | 617 | 0.320 |
Why?
| | Anxiety | 1 | 2016 | 966 | 0.320 |
Why?
| | Male | 19 | 2025 | 63681 | 0.320 |
Why?
| | Focus Groups | 2 | 2023 | 453 | 0.300 |
Why?
| | Female | 19 | 2025 | 68776 | 0.300 |
Why?
| | Public Health | 1 | 2013 | 484 | 0.290 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1279 | 0.280 |
Why?
| | Cytochrome P-450 CYP2C19 | 2 | 2024 | 23 | 0.270 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1220 | 0.270 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 5066 | 0.260 |
Why?
| | Delivery of Health Care | 2 | 2024 | 894 | 0.250 |
Why?
| | Behavior | 2 | 2019 | 92 | 0.250 |
Why?
| | Patient Participation | 2 | 2020 | 414 | 0.230 |
Why?
| | Treatment Outcome | 5 | 2020 | 10230 | 0.220 |
Why?
| | Pain | 1 | 2010 | 789 | 0.220 |
Why?
| | Aged, 80 and over | 4 | 2020 | 7086 | 0.220 |
Why?
| | Reproducibility of Results | 2 | 2022 | 3083 | 0.220 |
Why?
| | Disease Management | 2 | 2020 | 589 | 0.210 |
Why?
| | Naloxone | 1 | 2024 | 112 | 0.210 |
Why?
| | Program Evaluation | 2 | 2019 | 875 | 0.210 |
Why?
| | Prescriptions | 1 | 2023 | 66 | 0.210 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 156 | 0.210 |
Why?
| | Multifactorial Inheritance | 1 | 2024 | 150 | 0.200 |
Why?
| | Reminder Systems | 1 | 2025 | 174 | 0.200 |
Why?
| | Narcotic Antagonists | 1 | 2024 | 164 | 0.200 |
Why?
| | Antidepressive Agents | 2 | 2017 | 228 | 0.200 |
Why?
| | Text Messaging | 1 | 2025 | 149 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2012 | 0.190 |
Why?
| | Adult | 9 | 2024 | 35576 | 0.190 |
Why?
| | Evidence-Based Practice | 1 | 2024 | 212 | 0.190 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2441 | 0.180 |
Why?
| | Behavioral Symptoms | 2 | 2018 | 42 | 0.180 |
Why?
| | Inpatients | 1 | 2025 | 467 | 0.180 |
Why?
| | Risk Factors | 4 | 2024 | 9765 | 0.180 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 339 | 0.170 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 442 | 0.170 |
Why?
| | Evaluation Studies as Topic | 1 | 2020 | 173 | 0.170 |
Why?
| | Prospective Studies | 3 | 2016 | 7133 | 0.160 |
Why?
| | Obesity | 1 | 2013 | 2883 | 0.160 |
Why?
| | Surveys and Questionnaires | 3 | 2016 | 5406 | 0.160 |
Why?
| | Biological Specimen Banks | 1 | 2020 | 98 | 0.160 |
Why?
| | Grounded Theory | 1 | 2019 | 34 | 0.160 |
Why?
| | Sex Factors | 2 | 2015 | 1968 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 769 | 0.150 |
Why?
| | Curriculum | 2 | 2016 | 917 | 0.150 |
Why?
| | Evidence-Based Medicine | 2 | 2014 | 718 | 0.150 |
Why?
| | Medication Therapy Management | 1 | 2019 | 72 | 0.150 |
Why?
| | United States | 4 | 2018 | 13903 | 0.150 |
Why?
| | Residential Facilities | 1 | 2017 | 8 | 0.140 |
Why?
| | Models, Organizational | 1 | 2018 | 146 | 0.140 |
Why?
| | Independent Living | 1 | 2018 | 98 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2020 | 481 | 0.140 |
Why?
| | Medication Errors | 1 | 2017 | 95 | 0.130 |
Why?
| | Chronic Disease | 2 | 2020 | 1720 | 0.130 |
Why?
| | Precision Medicine | 1 | 2020 | 387 | 0.130 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 60 | 0.130 |
Why?
| | Telenursing | 1 | 2016 | 10 | 0.130 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 198 | 0.130 |
Why?
| | Cardiovascular Diseases | 2 | 2025 | 2004 | 0.120 |
Why?
| | Laxatives | 1 | 2015 | 19 | 0.120 |
Why?
| | Health Care Surveys | 1 | 2017 | 559 | 0.120 |
Why?
| | Office Visits | 1 | 2015 | 85 | 0.120 |
Why?
| | Perception | 1 | 2017 | 340 | 0.120 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2014 | 14 | 0.120 |
Why?
| | Quality Improvement | 2 | 2020 | 1103 | 0.120 |
Why?
| | Drugs, Investigational | 1 | 2014 | 32 | 0.110 |
Why?
| | PubMed | 1 | 2013 | 10 | 0.110 |
Why?
| | Systems Integration | 1 | 2014 | 38 | 0.110 |
Why?
| | Young Adult | 3 | 2016 | 12426 | 0.110 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 1902 | 0.110 |
Why?
| | Models, Educational | 1 | 2014 | 88 | 0.110 |
Why?
| | Interviews as Topic | 1 | 2016 | 717 | 0.110 |
Why?
| | Drug Combinations | 1 | 2013 | 330 | 0.090 |
Why?
| | Communication | 1 | 2017 | 846 | 0.090 |
Why?
| | Teaching | 1 | 2014 | 214 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4897 | 0.090 |
Why?
| | Adolescent | 3 | 2016 | 20393 | 0.090 |
Why?
| | Parasympatholytics | 1 | 2010 | 12 | 0.090 |
Why?
| | Antidiarrheals | 1 | 2010 | 15 | 0.090 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2010 | 27 | 0.090 |
Why?
| | Life Style | 1 | 2013 | 460 | 0.090 |
Why?
| | Dietary Fiber | 1 | 2010 | 51 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1098 | 0.080 |
Why?
| | Diarrhea | 1 | 2010 | 180 | 0.080 |
Why?
| | Abdominal Pain | 1 | 2010 | 144 | 0.080 |
Why?
| | Cohort Studies | 1 | 2019 | 5420 | 0.080 |
Why?
| | Clinical Competence | 1 | 2016 | 1017 | 0.080 |
Why?
| | Colorado | 2 | 2020 | 4421 | 0.070 |
Why?
| | Age Factors | 1 | 2015 | 3144 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2010 | 534 | 0.060 |
Why?
| | Drug Overdose | 1 | 2010 | 322 | 0.060 |
Why?
| | Phenethylamines | 1 | 2024 | 23 | 0.060 |
Why?
| | Cluster Analysis | 1 | 2022 | 482 | 0.050 |
Why?
| | Sulfonamides | 1 | 2024 | 496 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 35 | 0.040 |
Why?
| | Genotype | 1 | 2024 | 1839 | 0.040 |
Why?
| | Quality of Life | 1 | 2010 | 2704 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 443 | 0.040 |
Why?
| | Long-Term Care | 1 | 2017 | 92 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 385 | 0.030 |
Why?
| | Child | 1 | 2016 | 20883 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3381 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 539 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1368 | 0.030 |
Why?
|
|
Trinkley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|